ASCO 2026 Highlights Panel Discussion

Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Nancy Lin, MD; Erica Mayer, MD, MPH; and Jennifer Ligibel, MD, discuss important breast cancer research presented at the 2026 ASCO Annual Meeting.

October 15, 2026

Dana-Farber

Overview

The supplied article identifies a panel discussion by Harold Burstein, Sara Tolaney, Nancy Lin, Erica Mayer, and Jennifer Ligibel on breast cancer research presented at the 2026 ASCO Annual Meeting. The transcript and specific panel findings are not provided, so the discussion’s conclusions cannot be summarized from the available material.

Background

The 2026 ASCO Annual Meeting included breast cancer research spanning early-stage and metastatic disease, according to the supplied web research context. That context describes updates to ASCO guidance for stage I–III hormone receptor–positive, HER2-negative disease and follow-up, as well as updated ESMO metastatic breast cancer guidance. It also identifies SENOMAC as a 2026 trial report concerning omission of completion axillary lymph node dissection in selected patients. These contextual sources do not establish which topics or findings the panel discussed.

Data Highlights

No numerical results or trial data are provided in the article text or video transcript supplied. The contextual material mentions SENOMAC but does not provide numerical outcomes.

Key Findings

The panelists named in the article are Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Nancy Lin, MD; Erica Mayer, MD, MPH; and Jennifer Ligibel, MD.
The panel discussion concerns breast cancer research presented at the 2026 ASCO Annual Meeting.
The supplied material does not include the video transcript or specific statements made by the panelists.
The contextual research summary reports that SENOMAC examined omission of completion axillary lymph node dissection in clinically node-negative patients with one to two sentinel-node macrometastases; it does not provide numerical results.
The supplied context describes a 2026 ASCO living guideline for stage I–III hormone receptor–positive, HER2-negative breast cancer, but does not establish whether the panel discussed it.

Clinical Implications

The supplied article information does not report panel recommendations or specific clinical practice implications. The contextual guideline and trial descriptions should not be attributed to the panel without the transcript or additional source text.

Conclusion

The available material establishes the panel’s participants and subject but does not provide enough detail to report its discussion or conclusions. A transcript or fuller article text is needed to summarize the panel’s clinical findings.